Xing, Z.; Li, X.; He, Z.N.T.; Fang, X.; Liang, H.; Kuang, C.; Li, A.; Yang, Q.
IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma. Pharmaceutics 2024, 16, 870.
https://doi.org/10.3390/pharmaceutics16070870
AMA Style
Xing Z, Li X, He ZNT, Fang X, Liang H, Kuang C, Li A, Yang Q.
IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma. Pharmaceutics. 2024; 16(7):870.
https://doi.org/10.3390/pharmaceutics16070870
Chicago/Turabian Style
Xing, Zikang, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, and Qing Yang.
2024. "IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma" Pharmaceutics 16, no. 7: 870.
https://doi.org/10.3390/pharmaceutics16070870
APA Style
Xing, Z., Li, X., He, Z. N. T., Fang, X., Liang, H., Kuang, C., Li, A., & Yang, Q.
(2024). IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma. Pharmaceutics, 16(7), 870.
https://doi.org/10.3390/pharmaceutics16070870